November 20th, 2010
SHARP Shows Benefit for Vytorin in Chronic Kidney Disease
Larry Husten, PHD
The long-awaited SHARP study has turned up positive results for Vytorin (ezetimibe and simvastatin) in a population of patients with chronic kidney disease. Results of SHARP (Study of Heart and Renal Protection) were presented on Saturday at the American Society of Nephrology meeting in Denver and were scheduled to be posted online on the trial’s website. SHARP compared […]
October 1st, 2010
Chronic Kidney Disease and Cardiovascular Risk
Larry Husten, PHD
People with early-stage chronic kidney disease are at elevated risk for cardiovascular disease, according to a new study published in BMJ. Researchers from the U.K. and Iceland followed 17,000 adults in Reykjavik for a median of 24 years and found that people with chronic kidney disease at baseline had significantly elevated risk for cardiovascular events, […]
NEJM Journal Watch — Recent Cardiology Articles- More Data Support Semaglutide for Obesity-Related HFpEF, Regardless of Diabetes Diagnosis
- A Novel Agent Fails to Improve Outcomes in Diabetic Cardiomyopathy
- Persistent Symptoms After Valve Replacement for Severe Aortic Stenosis
- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?